F. HOFFMANN-LA ROCHE AG

Their core work

Roche is one of the world's largest pharmaceutical and diagnostics companies, headquartered in Basel, Switzerland. Within H2020, they contribute deep drug development expertise, preclinical and clinical safety data, and real-world patient datasets to large public-private research consortia — particularly through the Innovative Medicines Initiative (IMI). Their participation spans translational safety assessment, biomarker discovery, neurodegenerative disease research, and pediatric oncology, consistently acting as the industry data and expertise provider in multi-partner health projects. They also invest in emerging areas like organoid biology and AI-driven drug safety, bridging pharma-scale resources with academic research networks.

What they specialise in

How they've shifted over time

In the early period (2015–2018), Roche focused heavily on regulatory science, drug safety frameworks, and computational toxicology — projects like ADAPT-SMART, EU-ToxRisk, and eTRANSAFE centered on improving how drugs are assessed before reaching patients. From 2019 onward, the focus shifted markedly toward AI/machine learning, biomarker qualification, real-world data platforms, and advanced biological models like organoids and single-cell genomics. This mirrors the broader pharma industry pivot from traditional safety testing toward data-driven, personalized approaches to drug development.

Roche is moving from traditional preclinical safety assessment toward AI-powered, data-integrated drug development — expect future interest in federated health data, digital endpoints, and computational biology partnerships.

How they like to work

Roche overwhelmingly participates rather than leads — only 2 of 45 projects as coordinator, with 39 as participant. This is typical for large pharma in IMI-style consortia, where industry provides data, compounds, and domain expertise while academic partners lead the science. With 675 unique consortium partners across 32 countries, they function as a high-connectivity hub, plugged into virtually every major European health research network rather than working with a small circle of repeat partners.

Roche has collaborated with 675 distinct organizations across 32 countries, making it one of the most connected pharma participants in H2020 health research. Their network spans all major EU member states plus Switzerland, with particularly dense connections to academic medical centers, other large pharma companies (via IMI), and regulatory bodies.

What sets them apart

As one of the top-5 global pharma companies, Roche brings a combination that few partners can match: massive proprietary clinical and preclinical datasets, diagnostic platform capabilities (they own the diagnostics division), and the financial capacity to contribute in-kind to IMI projects without drawing EC funding. For consortium builders, partnering with Roche means access to industry-scale drug safety data, real-world evidence repositories, and a direct pipeline from research outputs to commercial drug development — something no academic or SME partner can offer.

Highlights from their portfolio

• ANTHROPOID
  One of only two projects Roche coordinated — an ERC-funded study using great ape organoids to study human brain evolution, unusually fundamental research for a pharma company (EUR 1M+ EC funding).
• eTRANSAFE
  Flagship translational safety project integrating preclinical and clinical data across pharma — directly tied to Roche's core drug safety expertise and their shift toward computational approaches.
• AIMS-2-TRIALS
  One of the largest and longest-running IMI projects (2018–2026) on autism, demonstrating Roche's sustained commitment to neuroscience and biomarker-driven clinical outcomes.